Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$153.29
-1.7%
$166.19
$56.10
$200.00
$6.12B-1.19183,636 shs8,845 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$39.60
0.0%
$33.72
$10.95
$40.26
$5.91B1.132.31 million shs183,505 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$4.82
+0.1%
$4.68
$1.57
$9.75
$1.69B1.514.90 million shs585,456 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$49.68
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-0.13%-1.99%-8.12%-16.96%+157.23%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
+0.03%+0.48%+0.15%+68.62%+227.79%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-4.52%+8.32%+7.38%-15.82%+137.19%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+0.04%+0.63%+40.34%+1,650.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$153.29
-1.7%
$166.19
$56.10
$200.00
$6.12B-1.19183,636 shs8,845 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$39.60
0.0%
$33.72
$10.95
$40.26
$5.91B1.132.31 million shs183,505 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$4.82
+0.1%
$4.68
$1.57
$9.75
$1.69B1.514.90 million shs585,456 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$52.95
$49.68
$2.65
$53.19
$6.12B-0.374.84 million shs6.35 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-0.13%-1.99%-8.12%-16.96%+157.23%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
+0.03%+0.48%+0.15%+68.62%+227.79%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-4.52%+8.32%+7.38%-15.82%+137.19%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+0.04%+0.63%+40.34%+1,650.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.63
Moderate Buy$202.3332.00% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.21
Hold$40.702.79% Upside
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
2.70
Moderate Buy$12.50159.61% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.27
Hold$55.144.13% Upside

Current Analyst Ratings Breakdown

Latest NUVB, BLTE, TERN, and CNTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingOutperform$20.00
5/5/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingOutperform$11.00
5/5/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingBuy$17.00
4/27/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
Reiterated RatingOutperformMarket Perform$58.00
4/26/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
DowngradeOutperformMarket Perform
4/22/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy$200.00
4/21/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingSell (D-)
4/20/2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
Reiterated RatingSell (D-)
4/20/2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
DowngradeOverweightEqual Weight$35.00 ➝ $42.00
4/16/2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Reiterated RatingOutperform$11.00
4/14/2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
Boost Price TargetOverweight$44.00 ➝ $44.50
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$15M393.92N/AN/A$3.27 per share12.11
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$62.90M26.61N/AN/A$0.92 per share5.23
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$9.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.30N/AN/AN/AN/A-19.49%-19.05%5/12/2026 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$197.53M-$1.47N/AN/AN/AN/A-60.37%-44.17%5/13/2026 (Estimated)
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%5/14/2026 (Estimated)

Latest NUVB, BLTE, TERN, and CNTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30N/AN/AN/AN/AN/A
5/13/2026Q1 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38N/AN/AN/AN/AN/A
5/12/2026Q1 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.60N/AN/AN/AN/AN/A
5/5/2026Q1 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/A-$0.52N/A-$0.52N/AN/A
5/4/2026Q1 2026
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million
3/31/2026Q4 2025
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.48-$0.10-$0.48$0.77 millionN/A
3/30/2026Q4 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/2/2026Q4 2025
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.56-$0.38+$0.18-$0.70N/AN/A
3/2/2026Q4 2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.11-$0.11N/A-$0.11$36.82 million$41.87 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
50.02
50.02
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.23
9.53
8.57
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
0.15
7.44
6.81
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
62.41
62.41

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
61.67%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
7.09%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
30.11%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1039.97 million34.65 millionNot Optionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200149.23 million138.65 millionOptionable
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
60347.60 million242.94 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
40115.52 million113.79 millionNot Optionable

Recent News About These Companies

Merck completes acquisition of Terns Pharmaceuticals
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck's Keytruda Surge: A Boost Amid Acquisition Costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$153.28 -2.72 (-1.74%)
As of 11:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$39.60 -0.02 (-0.04%)
As of 11:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Nuvation Bio stock logo

Nuvation Bio NYSE:NUVB

$4.82 +0.01 (+0.10%)
As of 11:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$52.95 0.00 (0.00%)
As of 05/5/2026 03:30 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.